Sharks are primitive creatures but their bodies produce a sophisticated substance that shows promise in fighting a range of human viruses from hepatitis to yellow fever, according to researchers.

The compound, called squala­mine, was discovered in 1993 but the study in the Proceedings of the National Academies of Sciences is the first to explore its potential use to combat human viruses.

Researchers tested squalamine – manufactured from dogfish sharks’ livers – in lab dishes and in animal subjects and found it could inhibit or control viral infections, and in some cases appeared to cure animals of their ills.

The project began when lead investigator, Michael Zasloff, professor of surgery and paediatrics at Georgetown University Medical Centre, sent samples of squalamine to a series of labs around the US for testing.

Squalamine has been synthesised in a lab since 1995 and is no longer extracted directly from shark tissue.

Tissue cultures showed it could “inhibit the infection of human blood vessel cells by the dengue virus and human liver cells infected with hepatitis B and D”, said the study. Research on animals showed the compound controlled yellow fever, Eastern equine encephalitis virus, and murine cytomegalovirus, a type of herpes virus that afflicts rodents.

“It is clearly a promising drug, and is unlike, in its mechanism of action and chemical structure, any other substance currently being investigated to treat viral infections,” Dr Zasloff said.

“We have not yet optimised squalamine dosing in any of the animal models we have studied and as yet we do not know the maximum protective or therapeutic benefit that can be achieved in these systems,” he added.

“But we are sufficiently convinced of the promise of squalamine as an antiviral agent that we intend to take this compound into humans.”

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.